Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Technology Research News June 29, 2005 Kimberly Patch	Physics maps city complexity Researchers used existing biological and social networking models to analyze city streets. Area traffic was directly proportional to the ease of navigation, and street grids were complicated as areas tried to avoid getting too much traffic.
Scientific American January 2009 Linda Baker	Removing Roads and Traffic Lights Speeds Urban Travel Urban travel is slow and inefficient, in part because drivers act in self-interested ways
Fast Company September 2009 Kate Rockwood	Janette Sadik-Khan Wants New Yorkers to Walk This Way Janette Sadik-Khan, Commissioner, New York City Department of Transportation, cut through the congested knots of Manhattan traffic with a novel concept: Close some roads to cars.
Popular Mechanics July 2006 Logan Ward	Highway of the Future: Interstate Intelligence Our nation's highways are being primed for a major transformation, one that will bring them into the wireless information age suitable for the wireless capabilities of our cars.
Technology Research News March 12, 2003	Net has few degrees of separation Researchers have found that the average number of connections needed to get from one point to another in real-world networks like the Internet and social networks is smaller than the number needed for randomly-connected networks. The findings could lead to improved networks.
CIO July 15, 2005 Megan Santosus	Stuck in Traffic? IT Can Ease the Commute Some methods of decreasing traffic involve heavy costs and manual labor, but there are technological workarounds. For example, some technologies relay detailed traffic information to properly equipped cars. Traffic signals can also be improved.
Wired December 2004 Tom McNichol	Roads Gone Wild It's no surprise that the Dutch, a people renowned for social experimentation in practically every facet of life, have embraced new ideas in traffic management. Other countries are following suite.
Technology Research News January 26, 2005 Kimberly Patch	Adaptive Lights Organize Traffic A researcher in Belgium has devised a way to allow traffic lights to self-organize to improve traffic flow. The method, which taps the self-organizing principles of social insects, does away with central control.
The Motley Fool September 30, 2009 Brian Orelli	Boston Scientific Pays Up And Johnson & Johnson reaps the rewards.
Reason March 2009 Adrian Moore & Sam Staley	A Better New New Deal How can we get the most bang for our transportation buck? Here are six ideas for the new president and cash-strapped governors.
Wired August 2008 Josh McHugh	Tom Vanderbilt's Why We Drive the Way We Do Unlocks How to Unclog Traffic Researcher uses mathematical algorithms to determine the best decisions to make when stuck in traffic.
The Motley Fool July 12, 2010 Brian Orelli	Johnson & Johnson MENDs a Hole Another neurovascular device maker, Micrus Endovascular, gets snatched up.
The Motley Fool May 20, 2009 Brian Orelli	Johnson & Johnson Tries to Pull a Travolta Johnson & Johnson seems to be making a comeback, after its drug-eluting stent market share fell precipitously to just 15% in the first quarter.
The Motley Fool July 14, 2008 Brian Orelli	Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut?
The Motley Fool June 15, 2011 Brian Orelli	Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market.
Fast Company October 19, 2011 Rachel Z. Arndt	Intelligent Cities Expo To celebrate the planners and engineers at this Hamburg expo, we've gathered some particularly smart urban solutions from around the world.
Wired November 2001 Dan Baum	The Ultimate Jam Session It takes more than technology to solve the world's traffic problems. While Singapore succeeds with an iron fist, the United States waits for the invisible hand...
BusinessWeek September 12, 2005 Larry Armstrong	Dodging That #%@! Traffic GPS systems can steer you around traffic jam-ups, but ease of use varies widely.
The Motley Fool October 12, 2004 Alyce Lomax	Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson?
The Motley Fool June 25, 2010 Brian Orelli	The Joys of Being Large and Diversified Johnson & Johnson's plant closure is a rounding error.
Reason April 2007 Staley & Balaker	How Traffic Jams Are Made In City Hall The bad logic and failed policies of American transportation planners.
The Motley Fool December 8, 2004 Dave Marino-Nachison	J&J Guided to Guidant? Medical device investors felt their hearts skip as executives told The New York Times the two companies may be set to merge.
The Motley Fool July 31, 2007 Nathan Parmelee	Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business.
InternetNews October 23, 2009	Juniper Hints at Networking Recovery Despite year-over-year declines, the networking player beats the Street and sees the first signs of an upturn in spending.
The Motley Fool May 26, 2010 Brian Orelli	Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues.
The Motley Fool June 4, 2010 Brian Orelli	Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other.
The Motley Fool October 19, 2011 Brian Orelli	Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson.
The Motley Fool July 19, 2011 Brian Orelli	J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile.
The Motley Fool June 28, 2011 Eric Bleeker	Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales?
The Motley Fool January 23, 2008 Brian Orelli	A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar.
The Motley Fool June 13, 2006 Jim Mueller	Foolish Investing and Boston Scientific In having bought Guidant, Boston Scientific might end up paying more than just the price. Investors, take note.
The Motley Fool May 28, 2010 Brian Orelli	How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem?
The Motley Fool July 14, 2009 Brian Orelli	J&J Eats a Hard Quarter Tough year-over-year comparisons are no match for the health care giant.
The Motley Fool January 18, 2012	What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance.
IndustryWeek February 16, 2011	Congested Highways Survey shows the actual cost of auto traffic delays.
The Motley Fool January 26, 2010 Brian Orelli	Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years.
The Motley Fool February 1, 2010 Brian Orelli	Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost.
BusinessWeek May 7, 2007 Kerry Capell	The Trouble With London's Traffic Tolls Since London imposed an ambitious congestion-pricing scheme in 2003, it has raised the fee to drive into the most heavily congested parts of town by 60%.
The Motley Fool December 1, 2010 Brian Orelli	We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell.
Popular Mechanics April 2009 Glenn Harlan Reynolds	Does High-Tech Highway Design Make us Less Safe? Tom Vanderbilt's latest book, Traffic: Why We Drive the Way We Do (and What It Says About Us), has a recurring theme: Making things safer may actually make them more dangerous.
The Motley Fool December 31, 2009 Brian Orelli	The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims.
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool November 21, 2008 Brian Orelli	Manufacturing Pain Johnson & Johnson has plenty of it.
Science News November 20, 2004 Ivars Peterson	Cruise Control and Traffic Flow A physicist at the University of Michigan has used computer simulations, applying concepts from statistical mechanics, to study how the use of adaptive cruise-control technology might affect traffic flow... Puzzle of the Week...
The Motley Fool August 27, 2010 Brian Orelli	A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much.
The Motley Fool February 27, 2008 Brian Orelli	Everyone's Picking on Anemia Drugs A new study in The Journal of the American Medical Association is adding fuel to the fire about Amgen's and Johnson & Johnson's anemia drugs. Should investors worry?
The Motley Fool February 28, 2011 Brian Orelli	Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo.
The Motley Fool August 14, 2007 Brian Orelli	A No-Win Situation Johnson & Johnson is suing the beloved American Red Cross for trademark infringement. Johnson & Johnson just needs to walk a fine line between having its brand eroded by the Red Cross and having its brand eroded by a public relations nightmare.
The Motley Fool April 29, 2011 David Williamson	Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes.
The Motley Fool May 25, 2005 Stephen D. Simpson	Stent Wars 2: The Market-Share Menace The battle for drug-coated stent market share between Johnson & Johnson and Boston Scientific may not be as exciting as watching Obi-Wan Kenobi and Anakin Skywalker fight, but the outcome matters for investors.